CLDI supply chain intelligence for Calidi Biotherapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Calidi Biotherapeutics, Inc. (CLDI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| COMPANY-A | COMPANY-A | 92% | On December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for contract research organization ("CRO") services and other clinica… |
| CITY-OF-HOPE | CITY-OF-HOPE | 90% | We procured the neural stem cell bank from City of Hope and we extended the cell bank at a commercial ready CDMO. |
| GENSCRIPT-PROBIO | GENSCRIPT-PROBIO | 90% | The CAL1virus for CLD-201 was manufactured at Genscript ProBio in China. |
| NORTHWESTERN-UNIVERSITY | NORTHWESTERN-UNIVERSITY | 90% | On June 7, 2021, the Company entered into a License Agreement (the "Northwestern Agreement") with Northwestern University ("Northwestern") for the exclusive commercialization rights to the investigat… |
| STEMVAC | STEMVAC | 90% | The development services provided by StemVac are highly specialized to meet our needs in developing a cost- and time-effective program as compared to services provided by an outsourced entity. |
| UNIVERSITY-OF-CHICAGO | UNIVERSITY-OF-CHICAGO | 90% | On July 22, 2021, the Company entered into an Exclusive License Agreement with the University of Chicago (the "University of Chicago Agreement") for patents jointly owned by the University of Chicago… |
| VETSTEM-BIOPHARMA | VETSTEM-BIOPHARMA | 90% | The AAA cell bank, VP-001, was produced by VetStem Biopharma. |
| EARLY-STAGE-CDMO | EARLY-STAGE-CDMO | 80% | Pilot and/or initial GMP batches for both product candidates (CLD-101 and CLD-201), should those programs advance, are anticipated to be produced by an early-stage CDMO on an as-need basis. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD | CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH | CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| GERMANY-CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD | GERMANY-CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| NEVADA-CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH | NEVADA-CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| NOVA-CELL-INC | NOVA-CELL-INC | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| NYSE-AMERICAN-LLC | NYSE-AMERICAN-LLC | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| QUARTERLY-REPORT-COMPANY | QUARTERLY-REPORT-COMPANY | 62% | tage of net sales generated for any product of the licensed patents for specific periods, and to pay up to $ 18.7 million if certain milestones are achieved during the clinical trials and post commer… |
| REDTAIL-BIOPHARMA-INC | REDTAIL-BIOPHARMA-INC | 62% | isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar… |
| STEMVAC-GMBH | STEMVAC-GMBH | 62% | urrent and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. Changes… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CLDI-DEBT-8673 | Warrants outstanding: 49440138 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| CLDI-DEBT-8674 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| CLDI-DEBT | Debt stack $2.6M | 90% | Market cache reports total debt of $2.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CLDI-OWNER-ARMISTICE-CAPITAL-LLC | ARMISTICE CAPITAL, LLC | 90% | 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 29 tracked holders. |